Home > Signaling Pathways>Apoptosis>c-RET>Regorafenib HCl (BAY-73-4506)
Regorafenib HCl (BAY-73-4506)

This product is for research use only, not for human use. We do not sell to patients.

Regorafenib HCl (BAY-73-4506)
For small sizes, please check our retail website as below: www.invivochem.com
Size Price Stock
500mg$500Check With Us
1g$880Check With Us
5g$1485Check With Us

Cat #: V0071 CAS #: 835621-07-3 Purity ≥ 98%

Description: Regorafenib HCl, the hydrochloric acid salt of regorafenib (also known as BAY 73-4506), is a potent inhibitor of multi-kinase including VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 values of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM in cell-free assays, respectively.

References: Wilhelm SM, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer, 2011, 129(1), 245-255.

Top Publications Citing Invivochem Products
Publications Citing InvivoChem Products

Product Promise

Promise
Molecular Weight (MW)519.28
Molecular FormulaC₂₁H₁₆Cl₂F₄N₄O₃
CAS No.835621-07-3
Storage-20℃ for 3 years in powder formr
-80℃ for 2 years in solvent
Solubility In VitroDMSO: >100 mg/mL (200.9 mM)r
Water: N/Ar
Ethanol: N/A
Solubility In Vivo30% PEG400+0.5% Tween80+5% Propylene glycol: 30mg/mL
SMILES CodeO=C(NC1=CC=C(C(C(F)(F)F)=C1)Cl)NC2=CC=C(OC3=CC(C(NC)=O)=NC=C3)C=C2F.O
SynonymsBAY 73-4506 hydrochloride); Regorafenib Hydrochlorid; Regorafenib HCl
ProtocolIn VitroRegorafenib potently inhibits VEGFR2 autophosphorylation in NIH-3T3/VEGFR2 cells with an IC50 of 3 nM. In HAoSMCs, regorafenib inhibits PDGFR-β autophosphorylation after stimulation with PDGF-BB, with an IC50 of 90 nM. Regorafenib inhibits the proliferation of VEGF165-stimulated HUVECs, with an IC50 of 3 nM.
In VivoRegorafenib effectively inhibits growth of the Colo-205 xenografts in the dose range of 10-100 mg/kg reaching a TGI of 75% at day 14 at the 10 mg/kg dose. In the MDA-MB-231 model, regorafenib is highly efficacious at a dose as low as 3 mg/kg, resulting in a significant TGI of 81%, which increases to 93% at doses of 10 and 30 mg/kg, where tumor stasis is reached.
These protocols are for reference only. InvivoChem does not independently validate these methods.
Preparing Stock Solutions
Solvent volume to be added Mass (the weight of a compound)
Mother liquor concentration 1mg5mg10mg20mg
1mM1.9257 mL9.6287 mL19.2574 mL38.5149 mL
5mM0.3851 mL1.9257 mL3.8515 mL7.7030 mL
10mM0.1926 mL0.9629 mL1.9257 mL3.8515 mL
20mM0.0963 mL0.4814 mL0.9629 mL1.9257 mL
Quality Control Documentation
The molarity calculator equation
Mass(g) = Concentration(mol/L) × Volume(L) × Molecular Weight(g/mol)
Mass
=
Concentration
×
Volume
×
Molecular Weight*
The dilution calculator equation
Concentration(start) × Volume(start) = Concentration(final) × Volume(final)

This equation is commonly abbreviated as: C1 V1 = C2 V2

Concentration(start)
C1
×
Volume(start)
V1
=
Concentration(final)
C2
×
Volume(final)
V2
Step One: Enter information below
Dosage mg/kg Average weight of animals g Dosing volume per animal µL Number of animals
Step Two: Enter the in vivo formulation
%DMSO + % + %Tween 80 + %ddH2O

Calculation Results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in µL DMSO(Master liquid concentration mg/mL) ,Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation: Take µL DMSO master liquid, next add µL PEG300, mix and clarify, next add µL Tween 80,mix and clarify, next add µL ddH2O,mix and clarify.
Note:
  • (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
  • (2) Be sure to add the solvent(s) in order.